RxDoctor Payments Data

Paul Patterson

Family · la Plata, MDNPI 1285639617

Payments from drug & device makers

$1,867in general payments, 2019–2025

Across 89 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$326
  • AstraZeneca$295
  • Lilly USA, LLC$237
  • AbbVie$220
  • Astellas Pharma US Inc$159
  • Boehringer Ingelheim$140
  • plus $490 from 12 others

What the payments were for

  • Food & beverage$1,76795%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,867 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$123,813
Medicare patients
287
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$39,215
OzempicSemaglutide33$36,658
JanumetSitagliptin Phos/Metformin Hcl24$36,603
JardianceEmpagliflozin25$31,723
EliquisApixaban30$29,884
FarxigaDapagliflozin Propanediol20$24,802
JanuviaSitagliptin Phosphate17$22,646
TrulicityDulaglutide17$22,161
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,411
Atorvastatin Calcium187$2,415
Rosuvastatin Calcium60$1,583
Metoprolol Succinate61$1,520
Levothyroxine Sodium119$1,367
Propranolol Hcl ErPropranolol Hcl14$1,237
Losartan Potassium68$1,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$237$61,37657 claims
Novo NordiskOzempic$326$36,65833 claims
Boehringer IngelheimJardiance$140$31,72325 claims
PfizerEliquis$46$29,88430 claims
AstraZenecaFarxiga$295$24,80220 claims
GSKTrelegy Ellipta$108$12,41120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in la Plata

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →